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Background: BceS-like histidine kinases strictly 
require BceAB-like ABC transporters for sensing 
of peptide antibiotics. 
Results: BceAB of Bacillus subtilis interacted 
with BceS in vivo and in vitro and specifically 
bound the substrate peptide bacitracin. 
Conclusion: Complex formation with the ABC-
transporter affects the activity of the histidine 
kinase. 
Significance: Histidine kinase and ABC-
transporter form a sensory complex for the 
detection of peptide antibiotics. 
ABSTRACT 
Resistance against antimicrobial peptides 
(AMPs) in many Firmicutes bacteria is 
mediated by detoxification systems that are 
comprised of a two-component regulatory 
system (TCS) and an ATP-binding-cassette 
(ABC) transporter. The histidine kinases of 
these systems depend entirely on the 
transporter for sensing of AMPs, suggesting a 
novel mode of signal transduction where the 
transporter constitutes the actual sensor. The 
aim of the present study was to investigate the 
molecular mechanisms of this unusual signaling 
pathway in more detail, using the bacitracin 
resistance system BceRS-BceAB of Bacillus 
subtilis as an example. To analyze the proposed 
communication between TCS and ABC 
transporter, we characterized their interactions 
by bacterial two-hybrid analyses and could 
show that the permease BceB and the histidine 
kinase BceS interact directly. In vitro pull-down 
assays confirmed this interaction, which was 
found to be independent of bacitracin. Because 
it was unknown if BceAB-type transporters 
could detect their substrate peptides directly or 
instead recognized the peptide:target complex 
in the cell envelope, we next analyzed substrate 
binding by the transport permease, BceB. 
Direct and specific binding of bacitracin by 
BceB was demonstrated by surface plasmon 
resonance spectroscopy. Finally, in vitro signal 
transduction assays indicated that complex 
formation with the transporter influenced the 
autophosphorylation activity of the histidine 
kinase. Taken together, our findings clearly 
show the existence of a sensory complex 
comprised of TCS and ABC transporter, and 
provide first functional insights into the 
mechanisms of stimulus perception, signal 
transduction and antimicrobial resistance 
employed by Bce-like detoxification systems. 
INTRODUCTION 
In recent years a number of cases were described 
where transport proteins act as co-sensors for 
bacterial signal transduction systems. Such 
transporters are able to interfere with signal 
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transduction processes for example by transporting 
effector molecules into the cytoplasm or by 
interacting directly with sensory components (1). 
The latter process is based on regulatory protein-
protein-interactions between the sensing unit, 
which harbors specificity for certain substrates, 
and the signaling unit, which transfers the 
information into the cytoplasmic compartment of 
the cell.  
One well-known example is the widespread 
Pst/Pho system, which senses environmental 
phosphate. Transcription of the genes for bacterial 
high-affinity phosphate transport systems is 
usually regulated by a two-component regulatory 
system (TCS)2, PhoBR in Gram-negative bacteria 
(2), PhoPR in Gram-positive bacteria (3,4) and 
SenX3-RegX3 in mycobacteria (5), where PhoR or 
SenX3 act as the histidine kinase (HK) and PhoB, 
PhoP or RegX3 act as the cognate response 
regulator. The TCS further requires the phosphate-
specific ATP-binding cassette (ABC) transporter 
PstSCAB and the peripheral membrane protein 
PhoU for signal-dependent activation (6). 
Together, transporter and HK are thought to form a 
membrane-bound repressor complex under 
phosphate-replete conditions (2), and mutations in 
the pstSCAB operon have been shown to lead to 
constitutive activation of the Pho regulon genes in 
a number of bacteria such as E. coli (7), 
Sinorhizobium meliloti (8), and Mycobacterium 
smegmatis (9). Further early indication that 
membrane transport and sensory transduction 
processes could be coupled in bacteria came from 
studies of the phosphoenolpyruvate-dependent 
sugar transport and chemotactic sensory system of 
E. coli (10). Regulation of C4-dicarboxylate uptake 
in E. coli is mediated by the TCS DcuS/DcuR and 
the secondary transporters DctA or DcuB. The HK 
DcuS is able to bind C4-dicarboxylates directly, but 
additionally requires the transporters DctA or 
DcuB as co-sensors under aerobic or anaerobic 
conditions, respectively (11). In dctA- or dcuB-
deficient strains, DcuS is deregulated and 
permanently active even in the absence of C4-
dicarboxylates (12). DcuS and the transporter 
DctA were shown to interact physically, 
suggesting the formation of a DctA/DcuS sensory 
complex to inhibit DcuS activity in the absence of 
its substrate (13). A similar set-up was recently 
shown to exist in B. subtilis (14). The CadC/LysP 
system of E.coli presents a further sensory 
complex consisting of a one-component signaling 
system and a secondary transporter. The central 
component of this system is the membrane-
integrated pH sensor and transcriptional activator 
CadC, which regulates induction of the cadBA 
operon under low pH. CadC activity is also 
dependent on the presence of lysine (15), and this 
lysine-dependent activation of CadC requires the 
co-sensor LysP, a lysine-specific permease (16). 
In all these signal transduction systems the 
accessory transporters act as inhibitors of their 
respective signal transduction system in the 
absence of the stimulus. In contrast, in the 
antimicrobial peptide detoxification systems 
studied here, activation of signaling depends 
entirely on a sensory transporter, and the system 
remains in an inactive state in the absence of the 
transporter (17-22). These systems are found 
widely spread among low GC Gram-positive 
bacteria and consist of a TCS where the HK lacks 
an obvious input domain, and an unusual ABC-
transporter of ten TM helices with a large 
extracellular domain (23,24). All examples 
characterized to date are involved in resistance 
against peptide antibiotics, and requirement for the 
transporter in signaling appears to be a conserved 
characteristic (25). 
The paradigm example for this is the 
BceRS-BceAB system of Bacillus subtilis, which 
mediates resistance against bacitracin (Fig. 1) 
(17,26). The HK BceS was found to be unable to 
detect bacitracin in the absence of the transporter 
BceAB, which led to the assumption that the 
transporter constitutes the sensory component of 
the system (17,27). Additionally, ATP-hydrolysis 
by the ATPase BceA, i.e. active transport, was 
shown to be essential for signaling (17). However, 
the mechanism by which the transporter and TCS 
communicate is not known. A comparative 
phylogenetic analysis of Bce-like modules showed 
a co-evolution between the transport permeases 
and HKs, suggesting direct interactions between 
the proteins (24), but clear experimental evidence 
for this is missing to date. A second open question 
concerns the mechanism of substrate binding and 
resistance by the transporter itself. Bacitracin 
inhibits cell wall synthesis by binding to 
undecaprenyl-pyrophosphate (UPP), the 
phosphorylated form of the carrier molecule for 
peptidoglycan precursors and thus prevents its 
recycling (28). Other peptide antibiotics, such as 
the lantibiotic nisin, often bind to the lipid II 
intermediate of peptidoglycan synthesis (29). Both 
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UPP and lipid II are found on the surface of the 
cell, and it is therefore not immediately obvious 
how a transporter can provide protection against 
antibiotics targeting these structures. Possible 
scenarios that have been discussed include removal 
of cell-associated peptides to the culture 
supernatant or import of the antibiotics for 
subsequent degradation (17,18,25). More recently 
it was proposed that BceAB might in fact not 
transport bacitracin at all but rather flip UPP to the 
cytoplasmic face of the membrane to prevent 
bacitracin binding (30). Addressing this important 
question is hampered by the lack of knowledge on 
the transporter’s true substrate: it is unclear if 
BceAB is able to bind free bacitracin as its 
substrate or if it instead recognizes a membrane-
associated UPP-bacitracin complex.  
To gain a better understanding of the 
molecular mechanisms of these unusual resistance 
determinants, we here set out to functionally 
characterize the Bce system of B. subtilis. Using 
both in vivo and in vitro approaches, we could 
demonstrate that the transporter BceAB is indeed 
able to interact directly with the TCS BceRS, with 
the permease and HK components providing the 
interaction scaffold. Additionally, we showed that 
BceB bound its substrate bacitracin directly, 
providing first insights into the mechanism of 
resistance. Furthermore, we show for the first time 
that complex formation with the transporter can 
influence the autophosphorylation activity of the 
HK in vitro. 
 
EXPERIMENTAL PROCEDURES 
Bacterial Strains and Growth Conditions. 
Escherichia coli and Bacillus subtilis were 
routinely grown in lysogeny broth (LB) medium 
(31) at 37 °C with agitation (200 rpm). During 
cloning of bacterial two-hybrid constructs, all 
media for E. coli were supplemented with 0.4 % 
(w/v) glucose. Selective media contained 
kanamycin (50 µg/ml), chloramphenicol (5 µg/ml), 
ampicillin (100 µg/ml) or erythromycin (1 µg/ml) 
and lincomycin (25 µg/ml) (mls). Solid media 
contained 1.5 % (w/v) agar. All strains used in this 
study are listed in Table 1; all primer sequences are 
listed in Table 2. 
Bacterial two-hybrid assays. To test protein-
protein interactions in the BceRS-BceAB module, 
translational fusions of the T18 and T25 domains 
of the adenylate cyclase CyaA of Bordetella 
pertussis were constructed for each Bce module 
protein individually. Additionally, BceAB was 
fused to the N-terminal end of T18 or the C-
terminal ends of T18 and T25. Furthermore, we 
generated a BceRS fusion to the C-terminal end of 
T18 (Table 1). Fusions were tested in pairwise 
combinations in E. coli BTH101 (32). Data are 
shown for the optimal pair for each protein 
combination. Of each transformation mixture, 10 
µl were spotted onto LB agar plates containing 0.5 
mM isopropyl-β-D-1-thio-galactopyranoside 
(IPTG) and 40 µg/ml 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (X-Gal) with selection for 
ampicillin and kanamycin resistance. Plates were 
incubated at 30 °C for 48 h. Formation of blue 
colonies was scored as a positive interaction result. 
To test for effects of bacitracin on the interaction 
between BceB and BceS, the corresponding pairs 
were also spotted on LB plates containing a linear 
gradient from 0 to 800 µg/ml bacitracin. 
In vivo assays of Bce-module functionality. 
To test for signaling activity, luciferase activities 
of strains harboring the PbceA-luxABCDE 
(pSDlux101) reporter, deletions of bceS or bceAB 
and respective complementation constructs were 
assayed as described previously (33).  
The sensitivity of B. subtilis strains to 
bacitracin was determined as the minimal 
inhibitory concentration (MIC). For this, serial 
two-fold dilutions of Zn2+-bacitracin from 32 
µg/ml to 2 µg/ml were prepared in Mueller-Hinton 
medium containing 0.2 % (w/v) xylose. For each 
concentration, 2 ml of media were inoculated at 
1:500 from overnight cultures grown in Mueller-
Hinton medium with xylose and selective 
antibiotics. Each culture was scored for growth 
after 20 to 24 h of incubation at 37 °C with 
agitation. The MIC was determined as the lowest 
bacitracin concentration where no growth was 
detected. 
Protein production. All proteins were 
produced in E. coli C43(DE3). Because BceAB 
consistently co-purified with a 38 kDa protein 
identified as ArnC by mass spectrometry analysis, 
the expression host strain for BceAB and BceS 
was deleted for the corresponding gene. 
The bceS coding region was amplified using 
primers 1895/1905, resulting in addition of a C-
terminal His8-tag, and cloned into the NcoI and 
PstI sites of pTrc99a, yielding pRU2401. To 
produce BceS-His8, cells were grown at 37 °C with 
agitation until the culture reached OD600 = 0.5, 
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induced with 1 mM IPTG and incubated for a 
further 2.5 h. Cells were then harvested by 
centrifugation at 5,400 × g for 15 min. The cell 
pellet was washed in buffer A (50 mM KPi [pH 
7.5], 150 mM NaCl, 5 mM β-mercaptoethanol (β-
ME), and 10 % (w/v) glycerol) and stored at -20 
°C until use. To purify BceS, cells were 
resuspended in buffer A supplemented with 0.1 
mM phenylmethylsulfonyl fluoride (PMSF) and 2 
mg DNaseI and disrupted by three passages 
through a French pressure cell (Thermo Fisher) at 
20,000 PSI. Unbroken cells were removed by 
centrifugation at 12,000 × g for 30 min, and the 
membranes were collected from the cell-free 
supernatant by ultracentrifugation at 180,000 × g 
for 1 h. Membranes were resuspended in buffer A 
and stored at -80 °C.  Solubilisation of membrane 
proteins was performed at a protein concentration 
of ~ 5 mg/ml in buffer A containing 0.5 % (w/v) n-
dodecyl-β-D-maltoside (DDM) with gentle stirring 
at 4 °C for 1.5 h The mixture was ultracentrifuged 
at 180,000 × g for 1 h. The supernatant (solubilized 
BceS) was then loaded onto a 1 ml Ni2+-NTA 
column (Qiagen) pre-equilibrated with 4 column 
volumes (CVs) buffer A containing 0.05 % (w/v) 
DDM. Loading was followed by washing with 5 
CVs buffer A and 5 CVs buffer A containing 50 
mM imidazole. BceS was eluted with buffer A 
containing 200 mM imidazole. All washing and 
elution steps were performed in the presence of 
0.05 % (w/v) DDM. Fractions containing BceS 
were pooled, protein concentrations determined 
with Roti®-Nanoquant (Carl Roth), and the 
proteins stored at 4 °C on ice until use. 
Construction of the bceAB expression 
plasmid pSDIBA501 was achieved by amplifying 
the bceAB coding region using primers 2256/2257 
and cloning the product into pASK-IBA5 via BsaI 
sites, resulting in an N-terminal fusion of a Strep-
tag® II to BceA. To produce Strep-BceAB, cells 
were grown at 37 °C with agitation for 1 h, 
followed by a shift in temperature to 30 °C and 
continued incubation until the culture reached 
OD600 = 0.5. The cells were induced with 50 ng/ml 
tetracycline, incubated for a further 2.5 h and 
harvested by centrifugation at 5,400 × g for 15 
min. The cell pellet was washed in buffer B (100 
mM Tris/HCl [pH 8.0], 150 mM NaCl, 5 mM β-
ME, and 10 % (w/v) glycerol) and stored at -20 °C 
until use. To purify BceAB, cells were disrupted 
and membranes isolated as described above. 
Membranes were resuspended in buffer B and 
stored at -80 °C. Solubilisation of membrane 
proteins was performed in buffer B containing 0.5 
% (w/v) DDM as mentioned before. The 
supernatant (solubilized BceAB) was loaded onto a 
1 ml Strep-Tactin® column (IBA) pre-equilibrated 
with 4 CVs buffer B containing 0.05 % (w/v) 
DDM. Loading was followed by washing with 4 
CVs buffer B. BceAB was eluted with buffer B 
supplemented with 2.5 mM D-desthiobiotin. All 
washing and elution steps were performed in the 
presence of 0.05 % (w/v) DDM. Fractions 
containing BceAB were pooled and concentrated 
approximately two-fold using a Vivaspin® 500 
centrifugal concentrator (Sartorius), protein 
concentrations were determined with Roti®-
Nanoquant (Carl Roth) and the proteins stored at 4 
°C on ice until use. To purifiy BceB alone, we 
generated pSD2401 by amplification of the bceAB 
coding region with primers 1525/2201. The 
product was digested with NcoI and SalI and 
cloned into pBAD24, resulting in the fusion of a 
Strep-tag® II to the C-terminus of BceB. To 
produce BceAB-Strep, cells were grown as 
described above, but here expression was induced 
with 0.02 % arabinose. To purify BceB the cells 
were treated as described for BceAB; BceA was 
completely removed during the washing step and 
only BceB found in the eluted fractions. 
Construction of the bceR expression plasmid 
pCF120 was achieved by amplifying the bceR 
coding region using primers 2007/2008. The 
product was digested with XhoI and BamHI and 
cloned into pET16b, resulting in an N-terminal 
fusion to a His10-tag. To produce BceR, cells were 
treated as described for BceS production. The cell 
pellet was washed in buffer C (20 mM KPi [pH 
7.5], 100 mM NaCl, 5 mM β-ME, and 10 % (w/v) 
glycerol) and stored at -20 °C until use. To purify 
BceR, cells were resuspended in buffer D (50 mM 
KPi [pH 7.5], 500 mM NaCl, 5 mM β-ME, 10 mM 
imidazole and 10 % (w/v) glycerol) supplemented 
with 0.1 mM PMSF and 2 mg DNaseI and 
disrupted by three passages through a French 
pressure cell (Thermo Fisher) at 20,000 PSI. 
Unbroken cells were removed by centrifugation at 
12,000 × g for 20 min and the cell-free supernatant 
was filtered through a 0.45 µm syringe filter before 
loading onto a 1 ml Ni2+-NTA resin column 
(Qiagen) pre-equilibrated with 5 CVs buffer A. 
Loading was followed by washing with 5 CVs 
buffer A, and 5 CVs buffer D and then with 5 CVs 
buffer D containing 100 mM imidazole. BceR was 
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eluted with buffer D supplemented with 250 mM 
imidazole. Fractions containing BceR were pooled, 
protein concentrations determined with Roti®-
Nanoquant (Carl Roth), and the proteins stored at 4 
°C on ice until use. 
Size exclusion chromatography of BceAB. 
Chromatography was performed using an ÄKTA 
FPLC system (GE Healthcare). Preparations of 
purified Strep-BceAB were incubated either alone 
or with 10 µg/ml bacitracin at 4 °C on ice for 20 
min followed by centrifugation at 13,000 rpm, 4 
°C for 10 min prior to resolution on a Superdex 
200 10/30 gel-filtration column (GE Healthcare). 
The proteins were resolved at a flow rate of 0.4 
ml/min using buffer B containing 0.05 % (w/v) 
DDM. Fractions (500 µl) were collected and 
analyzed by SDS/PAGE (12.5 % gel). The 
molecular weights were calculated from the elution 
volumes in comparison to a gel filtration LMW / 
HMW calibration kit (GE Healthcare). 
ATP-hydrolysis assays. ATPase activity was 
determined by a phosphate-release assay 
essentially as described by Monk et al. 1991 (34). 
In brief, 320 µl assay mixture contained 100 mM 
Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM β-ME, 10 
% (w/v) glycerol, 0.05 % (w/v) DDM, 10 mM 
MgCl2, 1 mM ATP and 1.2-12 µg purified BceAB. 
Reactions were started by the addition of ATP. 
After incubation at room temperature for 0 to 20 
min, 40 µl aliquots of the reaction were transferred 
to 96-well microplates, and the reaction was 
stopped by adding 5 µl SDS (4 % (w/v)). To each 
well 65 µl developing reagent (34) was added, and 
the absorbance at 660 nm was measured in a 
microtiter plate reader (Tecan Instruments) after 10 
min incubation at room temperature. The inorganic 
phosphate released from ATP was quantified in 
comparison to a standard curve of 0 to 100 nmol 
KPi in the reaction mixture, and suitable blanks 
were used to correct for nonspecific hydrolysis. 
Bacitracin binding by BceB using surface 
plasmon resonance (SPR) spectroscopy. SPR 
assays were performed in a Biacore T200 using 
carboxymethyl dextran sensor chips (Xantec 
CMD200-L) that were coated with Super-
Streptactin® resin (IBA, Göttingen). This is the 
first material that allows the complete regeneration 
of Strep-tagged molecules from a senor chip in a 
capturing SPR approach. Firstly, the chips were 
equilibrated with HBS-EP buffer (10 mM HEPES 
[pH 7.4], 150 mM NaCl, 3 mM EDTA, 0.005 % 
(v/v) detergent P20) until the dextran matrix was 
swollen. Then, two of the four flow cells of the 
sensor chips were activated by injecting a 1:1 
mixture of N-ethyl-N-(3-dimethylaminopropyl) 
carbodiimide hydrochloride and N-
hydroxysuccinimide using the standard amine-
coupling protocol. Both flow cells were loaded 
with a final concentration of 10 µg/ml of Super-
Streptactin® in 10 mM acetate pH 5.5 using a 
contact time of 420 s, so that the surfaces 
contained densities of 5,000-6,000 resonance units 
(RU). Free binding sites of the flow cells were 
saturated by injection of 1 M ethanolamine/HCl 
pH 8.0. Preparation of chip surfaces was carried 
out at a flow rate of 10 µl/min. Binding between 
BceB and bacitracin was analysed using a single 
cycle kinetic approach (35) with HBS-DDM buffer 
(10 mM HEPES [pH 7.4], 150 mM NaCl buffer, 
0.05 % (w/v) DDM). BceB carrying a C-terminal 
Strep-tag® II (20 µg/ml) was captured onto the 
second flow cell using a contact time of 300 s at a 
constant flow rate of 10 µl/min, followed by a 
stabilization time of 120 s so that approximately 
600-1000 RU of BceB were captured. Single cycle 
kinetics using Zn2+-bacitracin or nisin (control) 
were performed at a flow rate of 30 µl/min. 
Increasing concentrations (25, nM, 50 nM, 100 
nM, 250 nM, and 500 nM) of Zn2+-bacitracin or 
nisin, respectively, were then sequentially injected 
onto both flow cells without interim regeneration 
using a contact time of 180 s each and a final 
dissociation of 180 s. Then, the chip was 
regenerated by injection of 10 mM glycine pH 1.5 
for 60 s at a flow rate of 30 µl/min over both flow 
cells, which completely removed BceB from the 
Super-Streptactin® surface. Furthermore, blank 
single cycle kinetics were recorded by sequentially 
injecting buffer instead of increasing 
concentrations of bacitracin or nisin after capturing 
BceB-Strep. Each single cycle kinetic was 
performed four times in a row. All experiments 
were performed at 25°C. Sensorgrams were 
recorded using the Biacore T200 Control software 
1.0 and analyzed with the Biacore T200 Evaluation 
software 1.0. The surface of flow cell 1 was used 
to obtain blank sensorgrams for subtraction of bulk 
refractive index background. Buffer controls on the 
second surface were subtracted from the 
sensorgrams obtained with bacitracin or nisin to 
normalize drifts on the surface. The referenced 
sensorgrams were then normalized to a baseline of 
0. Peaks in the sensorgrams at the beginning and 
In vitro characterization of BceRS-BceAB 
 
6 
 
the end of the injections emerged from the runtime 
difference between the flow cells of each chip. 
In vitro pull-down assay. For in vitro 
interaction assays, 300 µg of purified BceS or a 
control protein were conjugated to N-
hydroxysuccinimide (NHS)-activated sepharose 
beads (GE Lifesciences). After blocking of 
unconjugated NHS-groups through extensive 
washing in buffer B containing 0.05 % (w/v) 
DDM, conjugated beads were stored at 4 °C in the 
same buffer as a 50 % (v/v) bead slurry. A typical 
experiment involved resuspending 50 µl of the 
bead slurry in buffer B containing 0.05 % (w/v) 
DDM and supplementing the suspension with 30 
µg test protein. After extensive washing, the beads 
were resuspended in 30 µl of 1 × SDS-PAGE 
sample buffer, beads were sedimented and 20 µl of 
sample buffer containing dissolved proteins were 
analyzed by SDS-PAGE using a 12.5 % 
polyacrylamide gel. For each experiment, beads 
conjugated with bovine serum albumin (BSA) or 
empty beads blocked by Tris through incubation in 
buffer B were used to control for incidental protein 
carry-over and non-specific binding of test proteins 
to conjugated protein or the sepharose bead matrix. 
Phosphorylation assays. To test 
phosphorylation of Bce-module proteins, 
equimolar mixtures (~ 300 pmol per protein in a 
190 µl reaction) of purified, detergent-solubilized 
protein were incubated with a mixture of [γ32P]-
ATP (0.01 mCi; 3000 Ci/mmol) and unlabelled 
ATP yielding a final concentration of 40 µM in 
phosphorylation buffer (100 mM Tris/HCl [pH 8], 
150 mM NaCl, 15 mM MgCl2, 5 mM β-ME, 0.05 
% (w/v) DDM and 10 % (w/v) glycerol) at room 
temperature. At different time points, 20 µl 
aliquots (~ 30 pmol per protein) were removed and 
mixed with SDS sample buffer. The sample for the 
t0 time point was taken immediately after addition 
of ATP. All samples were subjected to SDS-
PAGE. Gels were dried, and phosphorylated 
proteins were detected by PhosphorImager 
(Typhoon Trio™, GE Healthcare). The band-
intensities of the phosphorylated proteins were 
quantified using ImageJ by measuring the peak 
area of the corresponding peaks after substraction 
of the local background intensity for each band. 
RESULTS 
In vivo protein interactions within the Bce 
system. Since the signaling pathway within Bce-
like systems involves both the transporter and the 
HK (17,27), and since the protein families of 
BceB-like permeases and BceS-like HKs have co-
evolved (24), we proposed direct interactions 
between the two proteins. Initial experimental 
indication for this was obtained previously using a 
bacterial two-hybrid (BACTH) assay of BceS and 
BceB (33). Here we first wanted to test if 
additional protein-protein interactions between the 
transporter and TCS occurred. For this we applied 
a comprehensive BACTH analysis of the entire 
system, based on the in vivo reconstitution of 
adenylate cyclase activity from separate T18 and 
T25 domains of B. pertussis CyaA in E. coli 
(BTH101) (32). We generated fusions to the CyaA 
T18 and T25 domains of each protein individually 
(BceR, BceS, BceA and BceB). Additionally, 
plasmids were generated containing the complete 
transporter (bceAB) or TCS (bceRS) operon, to 
yield CyaA fusions of one component with 
concomitant production of the second, un-tagged 
protein. Pair-wise combinations were then 
introduced into E. coli BTH101 (Fig. 2). The T18-
BceS fusion showed positive results (i.e. blue 
colonies on indicator agar) with T25-BceS, as 
expected for homodimer formation. Moreover, an 
interaction of BceR with BceS was observed as 
expected, while homodimerisation of BceR was 
not found unless BceS was also supplied in the cell 
(T18-BceRS construct), suggesting that 
dimerization of the HK brought the BceR 
monomers into close proximity, or that 
phosphorylation of BceR by BceS induced 
dimerization of the regulator. We further found the 
expected association of the permease BceB with its 
cognate ATPase BceA in all combinations tested. 
The lack of a signal for BceB homo-dimerization 
is discussed in more detail below. 
As predicted from previous findings, we 
clearly observed interactions between BceS and 
BceB or BceAB. Addition of 0 to 800 µg/ml 
bacitracin to the indicator plates did not result in 
any changes of color intensity, suggesting that 
complex formation was not affected by the 
substrate antibiotic. More quantitative assays in 
liquid cultures were unsuccessful, most likely due 
to toxicity of BceAB overproduction in E. coli. 
Next we wanted to test interactions between the 
cytoplasmic and membrane-bound proteins of the 
system. For the ATPase BceA, no homo-
dimerization was found when produced alone, but 
in a combination where the permease was also 
present (BceA-T18 with T25-BceAB), interactions 
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between the ATPase domains were clearly 
observed. No interactions of BceA with the 
components of the TCS (BceS, BceR or BceRS) 
were observed. When BceR was produced in the 
absence of the HK, no interaction with the 
transporter (BceA, BceB and BceAB) was found. 
Interestingly however, when the T18-BceR fusion 
was co-expressed with the HK, positive results for 
interaction with BceAB and weakly with BceB 
were obtained. These data indicate that the 
regulator may be part of a membrane-associated 
protein complex of BceRS and BceAB but that this 
interaction requires the presence of both BceS and 
BceAB. Taken together, our data consistently 
show interactions between BceS and BceAB, and 
further suggest that together the HK and permease 
may form a scaffold for BceR to also interact with 
the complex.  
Purification of all protein components of 
the Bce-module. To further investigate the Bce 
system, we next wanted to analyze its activities in 
vitro. For this, we generated overproduction 
plasmids for the full-length proteins carrying 
affinity tags. For BceS production we chose a 
construct resulting in a C-terminal His8-tag fusion 
of BceS (Table 1). To produce BceAB, we cloned 
the corresponding operon into a vector that 
facilitated addition of an N-terminal Strep-tag to 
the ATPase (Table 1). To test if the affinity tags 
affected protein function, similar constructs 
harboring the tagged and untagged versions of 
bceS and bceAB were also introduced into B. 
subtilis and tested for functionality in bacitracin-
dependent signal transduction by complementation 
of the respective deletion strains. After 
introduction of bceS-His8 into TMB1557 (ΔbceS; 
PbceA-luxABCDE), BceS-His had comparable 
activities to the untagged protein (Fig. 3A left), 
thus showing full functionality despite the tag. 
Introducing Strep-bceAB into SGB79 (bceAB::kan; 
PbceA-luxABCDE) resulted in a slightly reduced 
promoter activity compared to the untagged 
version (Fig. 3A right). Further, the Strep-BceAB 
derivative was able to increase the resistance of a 
bceAB deleted strain (MIC = 2 µg/ml) four-fold to 
8 µg/ml, compared to a 16-fold (32 µg/ml) 
increase by the untagged protein, showing that the 
transporter retained at least partial activity despite 
the tag. 
After confirmation of functionality, both 
BceS-His8 and Strep-BceAB were overproduced in 
E. coli, where they were both found in the 
respective membrane fractions. Induction of BceS 
production resulted in the accumulation of large 
amounts of BceS, which migrated as a prominent 
36 kDa band during SDS–PAGE analysis (Fig. 
3B). This is consistent with the predicted 
molecular mass for BceS of 38 kDa. Induction of 
bceAB expression resulted in a moderate 
overproduction of BceA and BceB, which could be 
detected after SDS–PAGE as bands at 60 kDa for 
BceB, which is slightly below its expected 
molecular mass (72 kDa) but consistent with 
previous observations (33), and 27 kDa for BceA 
(expected mass: 27 kDa). Both BceS and BceAB 
could be solubilized using DDM and purified to 
high yields and apparent homogeneity using the 
respective affinity matrix. Additionally, BceR 
carrying a C-terminal His10-tag was produced in 
and purified from cytoplasmic factions of E. coli. 
The expected mass of BceR is 27 kDa, which is 
consistent with its observed migration on SDS-
PAGE gels. 
In vitro characterization of BceAB activity. 
As mentioned above, we observed no dimerization 
of BceB in the BACTH analysis (Fig. 2). 
Dimerization would have been expected for an 
ABC transporter, which generally consists of two 
membrane-bound permeases that provide a 
passageway for the cargo and two cytoplasmic 
nucleotide-binding domains that bind and 
hydrolyze ATP (36). However, the permease of the 
Bce system, BceB, possesses ten transmembrane 
(TM) helices, and a conserved domain analysis 
showed the presence of two FtsX-domains, one 
encompassing TM-helices 2 to 4 and the second 
encompassing TM-helices 8 to 10 (Fig. 4A). FtsX 
itself is the permease of an ABC transporter 
involved in regulation of cell wall hydrolases (37) 
and is predicted to consist of 4 TM-helices. It is 
therefore conceivable that BceB originated from a 
fusion of two smaller FtsX-domain permeases and 
thus does not require further dimerization. To test 
this in more detail we determined the molecular 
mass of the native transporter by size exclusion 
chromatography of detergent-solubilized BceB and 
BceAB. BceB alone eluted in a single peak 
corresponding to a molecular mass of 78 kDa, 
which is consistent with the theoretical mass of a 
BceB monomer of 72 kDa (Fig. 4B). Analysis of 
the BceAB complex showed two elution peaks. 
The second, smaller peak contained the ATPase 
BceA alone, which eluted at a volume 
corresponding to a mass of 29 kDa (theoretical 
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mass, 27 kDa). The first peak contained the 
BceAB complex and eluted at a mass of 112 kDa 
(Fig. 4C). In both analyses, the peak eluting with 
the void volume most likely contained aggregated 
protein and was not analyzed further. Importantly, 
no peak corresponding to the theoretical mass of 
200 kDa for a BceA2B2 complex was observed. 
Our results are therefore much more consistent 
with a transporter comprised of a single permease 
domain, thus confirming the observed lack of 
dimerization of the permease domains in the 
BACTH analysis. To further analyze the 
composition of the transporter complex, we 
quantified the band intensities for BceB and BceA 
from SDS-PAGE analysis of the peak fractions of 
two separate size exclusion analyses and obtained 
a BceB:BceA intensity ratio of 1.09 ± 0.08. Taking 
into account the 2.6-fold difference in mass 
between the permease (72 kDa) and the ATPase 
(27 kDa), the ratio in band intensities supports a 
composition of the BceAB transporter of one 
permease and two ATPase-domains (theoretical 
intensity ratio of 1.3). 
Next, we tested the ATP-hydrolysis activity 
of the purified transporter, however no hydrolysis 
was observed either in the presence or absence of 
the substrate bacitracin (data not shown), 
indicating that the transporter was not able to 
cleave ATP in the detergent-solubilized form. 
We then wanted to test whether BceAB 
directly interacted with its substrate peptide 
bacitracin. To test for direct binding of bacitracin 
by BceAB, we applied SPR spectroscopy. Because 
the BceAB complex was unstable when coupled to 
the sensor chip and both subunits dissociated over 
time, binding assays were performed with the 
isolated permease BceB. We applied a single cycle 
kinetic approach, where increasing concentrations 
of Zn2+-bacitracin were sequentially injected on a 
sensor chip with BceB captured to the surface. 
Nisin as a non-substrate peptide was used as 
control. Bacitracin showed a rapid association to 
BceB already at low nanomolar concentrations. 
The response units sequentially increased when 
higher the Zn2+-bacitracin concentrations were 
injected. The kinetic approach showed an 
association rate (ka) of 1.1 × 105 M*s, and a 
dissociation (kd) rate of 0.0015/s of Zn2+-bacitracin 
and BceB (Fig. 5A). The affinity of Zn2+-bacitracin 
to BceB at steady state was determined to be KD = 
60 nM (Fig. 5B). The non-substrate peptide nisin 
showed no binding to the BceB (Fig. 5B). 
Furthermore, absence of Zn2+ prohibited binding of 
bacitracin to BceB (data not shown), providing 
further evidence that the interaction of BceB is 
specific for Zn2+-bacitracin, the active form of the 
peptide (38). These data clearly show that the 
BceB subunit of the BceAB transporter directly 
and specifically interacts with free bacitracin with 
high affinity. 
BceAB and BceS interact in vitro. While 
the BACTH assays indicated complex formation 
between BceS and BceB (Fig. 2), these assays 
were performed under conditions where membrane 
proteins of a Gram-positive bacterium were over-
produced in a Gram-negative host. To confirm 
these results we therefore wanted to further 
characterize the interaction in vitro. For this, we 
chose an approach where full-length BceS was 
linked to a sepharose bead matrix via a chemically 
stable amide bond with an NHS-group. When 
BceS-coupled sepharose beads were mixed with a 
denaturing buffer and applied to SDS-PAGE, a 
distinct band corresponding to BceS was observed 
(Fig. 6A, “NHS-BceS”). This showed that not all 
BceS molecules were covalently bound to the 
beads, but that a fraction of the protein was 
attached via protein-protein interactions, most 
likely due to the typical homodimer formation of 
HKs. We then incubated the BceS-coupled beads 
with purified BceAB transporter (“Prey”). After 
extensive washing, BceAB remained bound to the 
beads and could be dislodged under denaturing 
conditions and detected via SDS-PAGE (Fig. 6A, 
“Pull-down”). This result shows that BceAB is 
able to bind to BceS in vitro. To exclude non-
specific interactions, we repeated the same 
experiment using bovine serum albumin (BSA) as 
prey protein, which showed no interaction with 
BceS-beads (Fig. 6B). When BSA was coupled to 
the beads or empty beads were blocked with Tris 
buffer, no binding of BceAB was observed (Fig. 
6C&D). We also tested whether the complex 
formation is affected by the addition of bacitracin, 
but no differences were observed (data not shown). 
Together, these results clearly show that the 
BceAB transporter and BceS HK specifically 
interact in vitro and that formation of this complex 
appears to be independent of the signal. 
Complex formation affects the 
autophosphorylation activity of BceS. As 
mentioned in the introduction, genetic data 
previously showed that the transporter triggers 
signal transduction in response to its substrate 
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antibiotic (17). We therefore next wanted to test if 
the transporter had an effect on the signaling 
activity of the TCS in vitro. For this, we first tested 
the autophosphorylation activity of detergent-
solubilized BceS. During incubation of BceS with 
[γ32P]-ATP, a radiolabelled band of the expected 
size appeared after 5 to 10 min, and further 
increased in intensity over time (Fig. 7A, top 
panel, Fig. 7B), showing that BceS had a low basal 
autophosphorylation activity in vitro. Addition of 
bacitracin had no effect (data not shown), 
consistent with in vivo data where BceS alone is 
unable to respond to the antibiotic. In the presence 
of the transporter a prominent radiolabelled band 
appeared at a size of 27 kDa (Fig. 7A, second 
panel). This corresponds to the molecular mass of 
the ATPase, and we could indeed also observe this 
band when BceAB alone was incubated with 
[γ32P]-ATP (not shown). It therefore appears that 
the ATPase is able to bind ATP despite its 
inactivity to hydrolyze it in vitro. The band 
intensity of the HK was reduced by about 50 % in 
the presence of the transporter (Fig. 7A&C), 
indicating a lower autophosphorylation rate in the 
complex compared to BceS alone (p = 0.009, two-
way ANOVA). The difference in phosphorylation 
activity of BceS is unlikely to be simply due to 
reduced access to ATP caused by the observed 
ATP binding by BceA, because the protein 
concentration (1.4 µM) is too low to significantly 
impact on the total ATP concentration (40 µM) in 
the assay, even if every BceA molecule were to 
bind an ATP molecule. We therefore interpret the 
data as a true reduction of HK activity in its 
uninduced state by the transporter as discussed in 
more detail below. 
Phosphotransfer from BceS to BceR only 
occurred at a very low rate as seen by the weak 
signal for BceR after 30 to 60 min when BceS and 
BceR were both incubated in an equimolar ratio 
(Fig. 7A&C). Surprisingly, when the regulator was 
incubated with the transporter BceAB in the 
absence of the HK a weak but distinct band of 
BceR-32P was observed (Fig. 7A&C). However, 
this observed HK-independent in vitro 
phosphorylation of BceR in the presence of BceAB 
is not likely to be of biological significance, 
because in a strain of B. subtilis carrying BceR and 
BceAB but not BceS, no target promoter activities 
above background were detected 4. 
When all module components were 
incubated together, BceS had the same 
phosphorylation rate as in a combination of only 
BceS and BceAB (Fig. 7A&B), showing no further 
effect on autophosphorylation. The same was true 
for the BceR band, which showed the same 
intensity as when incubated with BceAB alone 
(Fig. 7A&C). This indicates that BceAB was not 
able to influence phosphotransfer under the chosen 
assay conditions. Furthermore, the addition of 
bacitracin showed no effect on band intensities 
(Fig. 7A, bottom panel). This inability of the 
system to respond to its stimulus in vitro is 
consistent with the lack of ATP-hydrolysis by the 
transporter under the same conditions, because it 
was shown previously that signaling is abolished 
with an ATPase defective transporter (17). 
Therefore, our assay conditions monitor only the 
ground state of the signaling pathway. 
Nevertheless, the significant reduction of the BceS 
autophosphorylation rate in the presence of BceAB 
indicated that the transporter was indeed able to 
directly influence the HK’s basal activity.  
DISCUSSION 
In former studies it was shown that BceS-like HKs 
have an absolute requirement for BceAB-type 
transporters in perception of antimicrobial 
peptides, not only in the model organism B. 
subtilis, but also in medically and 
biotechnologically relevant Gram-positive species, 
such as S. aureus, Enterococcus faecalis or 
Lactobacillus casei (18,21,22). Besides the 
unusual mode of signalling, the mechanism of 
resistance provided by a transporter against 
antibiotics that are active on the cell surface 
remains enigmatic. The aim of the present study 
was to investigate the molecular mechanisms 
underpinning these resistance systems in more 
detail, using the bacitracin resistance system 
BceRS-BceAB of B. subtilis as an example.  
BceAB forms a sensory complex with BceS. 
The observation that signalling in Bce-like systems 
requires an active transporter could be explained 
by different conceivable scenarios. One 
explanation might be that the transporter is 
required to actively move the substrate peptide to a 
location where it can then be sensed directly by the 
HK. An alternative hypothesis is that the 
transporter and TCS communicate directly via 
protein-protein interactions. A direct interaction of 
BceS-like HKs and BceB-like transporters was 
proposed previously based on protein co-evolution 
(24). A BACTH approach in S. aureus provided 
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first experimental evidence for this, showing 
interactions between the HK GraS, the transport 
permease VraG and the accessory membrane 
protein GraX (20). Here we showed that in the 
Bce-system of B. subtilis, which lacks a 
homologue of the GraX protein, BceB and BceS 
could also interact in a BACTH assay (Fig. 2). We 
further confirmed these results by in vitro pull-
down of BceAB by BceS (Fig. 6), showing a direct 
and specific interaction between the purified HK 
and ABC transporter. We could not find any effect 
of bacitracin on this interaction, suggesting that the 
complex is formed constitutively, independent of 
the signal. Together, our data clearly demonstrate 
that BceRS and BceAB form a sensory complex 
through the direct interaction between BceS and 
BceB. The BACTH analysis appeared to indicate 
that BceR could also interact with this complex as 
long as all membrane-bound components were 
present, suggesting that the signalling complex 
may be comprised of all four proteins of the 
system. As mentioned in the Methods section, 
BceAB consistently co-purified with the E. coli 
protein ArnC, which catalyzes an undecaprenyl-
phosphate-dependent transfer reaction during lipid 
A modification (39). Because this modification 
pathway is involved in resistance of E. coli against 
polymyxin A, which, like bacitracin, is a non-
ribosomally synthetized cyclic peptide antibiotic, 
this may point to a more general significance of the 
protein-protein interactions studied here beyond 
Firmicutes bacteria. 
Direct binding of bacitracin by BceB. 
BceAB-like transporters confer resistance against 
antimicrobial peptides that bind to targets in the 
cytoplasmic membrane (28,40), leading to the 
speculation that such transporters may not directly 
recognize the peptides as substrates, but rather the 
target:peptide complex in the membrane (17,27). 
Taking this hypothesis one step further, it was 
recently proposed that BceAB of B. subtilis does 
not transport bacitracin at all, but instead acts by 
flipping the target molecule UPP to the 
cytoplasmic side of the membrane (30). To address 
this important question, we here used SPR 
spectroscopy to test if the permease BceB could 
bind bacitracin in the absence of the native 
membrane environment. Our results clearly 
showed high-affinity binding of bacitracin with a 
steady-state KD of 60 nM. This interaction was 
specific for the active form, i.e. the Zn2+-complex, 
of bacitracin, as no binding was observed in the 
absence of Zn2+, or with the non-substrate peptide 
antibiotic nisin (Fig. 5). Moreover, the KD obtained 
in vitro for the purified permease very closely 
matches the in vivo threshold concentration of 
bacitracin required for activation of the target 
promoter, PbceA, of 70 nM 3, supporting the 
physiological relevance of the in vitro data. While 
the results obtained here do not exclude the 
possibility that a bacitracin:UPP complex can also 
be recognized by the transporter, they certainly 
lend weight to a model for a resistance mechanism 
involving translocation of the antimicrobial peptide 
directly, rather than flipping of the cellular target 
molecule. 
BceAB affects the autophosphorylation of 
BceS. To study the influence of BceAB on 
signalling, we reconstructed the signal transduction 
pathway in vitro using the purified Bce-
components and monitored protein 
phosphorylation from radiolabeled [γ32P]-ATP 
over time (Fig. 7). The results showed that the 
activity of BceS was reduced in the presence of the 
transporter, suggesting that in the complex the 
transporter inhibited signal-independent 
autophosphorylation of BceS, presumably via the 
direct protein-protein-interactions shown above 
(Figs. 2 & 6). Activation of signalling by 
bacitracin could not be shown in vitro, probably 
due to the observed inability of the transporter to 
hydrolyse ATP under the test conditions, which 
may be a consequence of the absence of a 
phospholipid environment for the transporter and 
lacking lateral pressure in detergent micelles. This 
finding is consistent with earlier observations that 
ATP-hydrolysis is absolutely required for 
signalling in vivo (17,18). We therefore concluded 
that we here assayed the ground-state of the 
system, reflecting phosphorylation activities in the 
absence of active signalling. Explanation of the 
results from the phosphorylation assays is further 
complicated by the observed HK-independent 
phosphorylation of the response regulator in the 
presence of the ABC-transporter, which cannot 
currently be explained and demands some caution 
in interpretation of the data. Nevertheless, BceAB 
was able to reduce the signal-independent 
autophosphorylation activity of BceS in vitro, 
which suggested that the transporter was able to 
directly influence the activity of its cognate HK. 
Future efforts will be directed at elucidating the 
molecular details of this effect and how it is 
influenced by the presence of bacitracin. 
In vitro characterization of BceRS-BceAB 
 
11 
 
 Based on the data obtained in the present 
study and in previous genetic and comparative 
genomic analyses (17,24,33), we here propose a 
working model for the mechanism of signal 
transduction within Bce-like models (Fig. 1). The 
signalling complex is comprised of the HK and the 
transporter, which most likely consists of a single 
permease subunit and two ATPase domains (Fig. 
4). A potential involvement of the response 
regulator has been discussed above. In the presence 
of bacitracin, the peptide is bound directly by the 
transporter. The resulting transport activity, as 
implied from the previously reported requirement 
for ATP-hydrolysis by the transporter (17), then 
triggers activation of the HK. The exact 
mechanism for this remains unknown to date, but 
based on the constitutive complex formation 
observed here it appears likely to involve direct 
communication via protein conformational 
changes. Autophosphorylation of the HK leads to 
phosphorylation of the response regulator and in 
turn to an increased transcription from the target 
promoter, PbceA. The resulting elevated cellular 
levels of the ABC-transporter ultimately lead to 
resistance, most likely by active removal of the 
antimicrobial peptide from its site of action. 
Taken together, the present study provides 
first functional insights into the mechanisms of 
stimulus perception, signal transduction and 
resistance by Bce-like systems, which represent 
widely spread resistance determinants against 
peptide antibiotics in Firmicutes bacteria.
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FIGURE LEGENDS 
Figure 1: Working model for the BceRS-BceAB bacitracin resistance system of Bacillus subtilis. 
Bacitracin is bound directly by the transporter BceAB. BceAB and BceS interact to form a sensory 
complex in the membrane. ATP-hydrolysis by the transporter triggers the activation of BceS, which in turn 
leads to phosphorylation of BceR. Activation of the target promoter (PbceA) by BceR then induces 
increased production of BceAB to ensure resistance. Interactions between proteins are marked by double 
headed arrows; events relating to transcription are labelled with dotted arrows; the potential interaction of 
BceR with the sensory complex of BceS and BceAB is indicated with a question mark.  
 
Figure 2: Bacterial two-hybrid analysis of the BceRS-BceAB module. Hybrids consisting of B. 
pertussis CyaA T18 or T25 domains and each individual Bce protein or the complete transporter (BceAB) 
or TCS (BceRS) were introduced into E. coli BTH101. Cells were spotted onto LB plates containing X-Gal 
(40 µg/ml), IPTG (0.5 mM), and antibiotics for selection. Pictures were taken after 48 h of incubation at 30 
°C. The blue colonies indicating positive results for interaction are depicted as dark gray in the gray-scale 
image. 
 
Figure 3: (A) Signal transduction activities of affinity-tagged BceAB and BceS. Exponentially growing cells 
of strains carrying the PbceA-luxABCDE reporter were challenged with 30 µg/ml Zn2+-bacitracin (+) or left 
untreated (-). Luminescence (relative luminescence units, RLU) was measured at 48 min post-induction. 
Luminescence was normalized to cell density and is expressed as RLU/OD600. The left graph shows 
complementation of bceS-deletion by untagged (left) and His-tagged (right) BceS. The right graph shows 
complementation of bceAB-deletion by untagged (left) and Strep-tagged (right) BceAB. Data are shown as 
the mean and standard deviation of four independent experiments. (B) Affinity purification of BceAB, BceS 
and BceR from E. coli C43(DE3) cells. Left panel: BceS with a C-terminal His8-tag was purified with a Ni2+-
NTA column. Center panel: BceAB carrying an N-terminal Strep II®-tag on the ATPase domain was 
purified via a Strep-Tactin® column. Right panel: BceR carrying a C-terminal His10-tag was purified with a 
Ni2+-NTA column. Proteins were analysed using SDS-PAGE and gels were stained with Coomassie 
Brilliant Blue. Purified proteins are indicated on the right by the last letter of their name. A molecular size 
marker is indicated on the left in kDa. MF; membrane fraction. S; solubilized fraction. E; Elution. CF; 
cytoplasmic fraction. 
 
Figure 4: Size exclusion analysis of the BceAB complex. (A) Conserved domain analysis of BceB. TM 
helices are shown as black rectangles. FtsX-domains are indicated by dashed boxes. Predictions were 
done using the SMART-database (41). (B, C) Size-exclusion analysis of BceB (B) and BceAB (C) on a 
Superdex 200 10/30 column. (C) The left panels show the chromatograms. The vertical dashed line 
indicates the void volume (V0) of the column. The calculated molecular mass corresponding to the major 
eluted peaks is shown in parentheses, and eluted proteins are given by the last letter of their name. The 
right panels show the corresponding SDS-PAGE analysis of the fractions indicated by numbers below the 
chromatograms. A molecular size marker is indicated on the left in kDa; proteins are indicated on the right 
by last letter of their name. 
 
Figure 5: Binding of bacitracin to BceB. SPR spectroscopy was used to quantify interactions between 
BceB and Zn2+-bacitracin or nisin. BceB-Strep was captured onto a Super-Streptactin®-coated chip before 
increasing concentrations of Zn2+-bacitracin or nisin (control) were injected. (A) Single cycle binding kinetic 
of bacitracin binding to BceB. The grey line shows the recorded sensorgram, the black line shows the 
fitted sensorgram. (B) Steady state affinity of bacitracin (black) and nisin (grey) to BceB.  
 
Figure 6: In vitro pull-down assay using NHS-activated sepharose. Each panel shows the fraction 
containing all proteins eluted from the beads (Pull-down), as well as the purified protein tested for 
interaction with the beads (Prey). In panel A, NHS-conjugated BceS (NHS-BceS) and the last washing 
step before elution (Wash) are also shown. The protein conjugated to the beads (Bait) is given below each 
panel. (A, B) NHS-conjugated BceS incubated with purified BceAB (A) or BSA (B). (C) NHS-conjugated 
BSA incubated with purified BceAB. (D) NHS-Sepharose blocked with Tris, incubated with purified BceAB. 
BceAB eluting specifically from NHS-BceS beads is indicated by star symbol. Proteins were analysed 
using SDS-PAGE and gels were stained with Coomassie Brilliant Blue. A molecular size marker is 
indicated on the left in kDa, and the protein bands are labelled on the right. 
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Figure 7: In vitro phosphorylation of Bce module proteins. Purified, detergent-solubilized BceS-His8 
was mixed in equimolar ratios with BceAB, BceR or both as indicated on the left. (A) Phosphorylation was 
started at t = 0 min by adding [γ32P]-ATP. At the indicated times, reactions were stopped, the samples 
subjected to SDS-PAGE and phosphorylated proteins detected by phospho-imaging. Representative 
autoradiographs of three to four independently performed experiments are shown. (B, C) Band intensities 
of BceS-32P (B) and BceR-32P (C) were quantified and plotted over time. The protein combinations in each 
assay are given on the right by the last letter of their names. Data are shown as the mean ± standard 
deviation of three to four independently performed experiments. 
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TABLES 
TABLE 1  
Plasmids and Strains used in this study 
 
Plasmid or Strain Descriptiona Reference or source 
Plasmids 
pASK-IBA5 plus 
 
Vector for tetracycline-inducible gene expression; carries an N-
terminal Strep-tag II® sequence; Ampr 
 
Iba 
pTrc99a Vector for IPTG-inducible gene expression; Ampr (42) 
pET16b Vector for IPTG-inducible gene expression; carries an N-terminal 
His10-tag sequence; Ampr 
Novagen 
pBAD24 Vector for arabinose-inducible gene expression; Ampr (43) 
pBS2E Empty vector for integration at amyE; Ampr; mlsr (44) 
pKT25 Vector for translational fusions of cyaA T25 fragment to N-terminus of 
insert polypeptide; lac promoter; Kanr 
(32) 
pKTN25 Vector for translational fusions of cyaA T25 fragment to C-terminus of 
insert polypeptide; lac promoter; Kanr 
(32) 
pUT18 Vector for translational fusions of cyaA T18 fragment to C-terminus of 
insert polypeptide; lac promoter; Ampr 
(32) 
pUT18C Vector for translational fusions of cyaA T18 fragment to N-terminus of 
insert polypeptide; lac promoter; Ampr 
(32) 
pSDIBA501 pASK-IBA5C-bceAB  This study 
pSD2402 pBAD24-bceAB-Strep This study 
pRU2401 pTrc99a-bceS-His8 This study 
pCF120 pET16b-bceR-His10 This study 
pNT2E07 pBS2E-Pxyl-bceS This study 
pNT2E01 pBS2E-Pxyl-bceAB This study 
pSD2E01 pBS2E-Pxyl-bceS-His8 This study 
pSD2E02 pBS2E-Pxyl-Strep-bceAB This study 
pAS1803 pUT18-bceS (33) 
pAS2503 pKT25-bceS This study 
pCF18C01 pUT18C-bceR This study 
pCF2501 pKT25-bceR This study 
pCF18C02 pUT18C-bceRS This study 
pAS1804 pUT18-bceA (33) 
pAS2504 pKT25-bceA This study 
pAS1805 pUT18-bceB This study 
pAS2505 pKT25-bceB (33) 
pHF1804 pUT18-bceAB This study 
pHF2509 
 
pKT25-bceAB 
 
This study 
E.coli strains   
XL1-blue 
 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
lacIqZ∆M15 Tn10 Tetr] 
 
Stratagene 
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DH5α 
 
fhuA2 lac(Δ)U169 phoA glnV44 Φ80' lacZ(Δ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
(45) 
BTH101 F-, cya-99, araD139, galE15, galK16, rpsL1, hadR2, mcrA1, mcrB1 Euromedex 
C43(DE3) F– ompT gal dcm hsdSB(rB- mB-)(DE3) (46) 
SGE217  
B. subtilis strains 
TMB1557 
C43(DE3); arnC::kan 
 
ΔbceS;  sacA::PbceA-luxABCDE 
This study 
 
This study 
SGB79 bceAB::kan;  sacA::PbceA-luxABCDE This study 
SGB276 ΔbceS;  sacA::PbceA-luxABCDE; lacA::Pxyl-bceS-His8 This study 
SGB277 bceAB::kan;  sacA::PbceA-luxABCDE; lacA::Pxyl-Strep-bceAB This study 
TMB1650 ∆bceS; sacA::PbceA-luxABCDE; lacA::Pxyl-BceS This study 
TMB1636 bceAB::kan; sacA::PbceA-luxABCDE; lacA::Pxyl-bceAB This study 
SGB276 ∆bceS; sacA::PbceA-luxABCDE; lacA::Pxyl-BceS-His8 This study 
SGB277 bceAB::kan; sacA::PbceA-luxABCDE; lacA::Pxyl-Strep-bceAB This study 
a	  Ampr, ampicillin resistance; kanr, kanamycin resistance; mlsr, macrolide-lincosamide-streptogramin B resistance 
 
TABLE 2  
Primers used in this study 
 
Name Sequence (5-̍3 ̍)a 
Used for 
amplification of  
2256 AATTGGTCTCAGCGCCATGGTGATTTTAGAAGCG Strep-bceAB (fwd) 
2257 AATTGGTCTCGTATCACAACGACGATTTAATG Strep-bceAB (rev) 
2007 ATCGCTCGAGTTGTTTAAACTTTTGCTGATTG bceR-His10 (fwd) 
2008 ATCGGGATCCTTAATCATAGAACTTGTCCTC bceR-His10 (rev) 
1895 AATTCCATGGTTAAAGCATTCCTTATCGAAAGG bceS-His8 (fwd) 
1905 AATTCTGCAGTCAGTGATGGTGATGGTGATGGTGATGCACGCTTAT
GACATGTTCAAATTG 
bceS-His8 (rev) 
1525 AATTCCATGGTGATTTTAGAAGCGAA bceAB-Strep (fwd) 
2201 AATTGTCGACTTATTTTTCGAACTGCGGGTGGCTCCAGCCACCGCCA
CCGCCACCCAACGACGATTTAATGACC 
bceAB-Strep (rev) 
1355 GTCATCTAGAGATGATTAAAGCATTCCTTATCG bceS (fwd) BACTH 
1356 GTCAGGTACCTGCACGCTTATGACATGTTC bceS (rev) BACTH 
1359 GTCATCTAGAGATGAACATTAATCAGCTCATCC bceB (fwd) BACTH 
1360 GTCAGGTACCTGCAACGACGATTTAATGACC bceB (rev) BACTH 
1357 GTCATCTAGAGATGGTGATTTTAGAAGCG bceA (fwd) BACTH 
1358 GTCAGGTACCTGATGTTCATGCTGCACC bceA (rev) BACTH 
3218 AATTTCTAGAGTTGTTTAAACTTTTGCTGATTGAAG bceR (fwd) BACTH 
3219 AATTGGTACCTGTTAATCATAGAACTTGTCCTCTTC bceR (rev) BACTH 
a Restriction sites are shown in bold; nucleotides encoding the His8-tag are shown in underlined italics; nucleotides encoding the 
Strep-tag are shown in italics.  
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